Kura Oncology (KURA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

KURA · Stock Price

USD 9.32+3.56 (+61.81%)

Market Cap: $832.6M

Historical price data

Market Cap: $832.6MPipeline: 21 drugs (1 Phase 3)Patents: 20Founded: 2014HQ: San Diego, United States

Sector Ranking#190 in Small Molecule Drugs #57 in Oncology (General)

Overview

Kura Oncology's mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives. The company has built a clinical-stage pipeline anchored by a deep scientific understanding of cancer biology, particularly the RAS pathway, and is advancing programs like tipifarnib (FTI), KO-2806 (FTA), and ziftomenib (menin inhibitor) in targeted populations and rational combinations. Its strategy focuses on expanding patient populations and leveraging combination therapies to overcome resistance, aiming to deliver durable remissions in areas of significant unmet need such as HRAS-mutant head and neck squamous cell carcinoma (HNSCC) and NPM1-mutant acute myeloid leukemia (AML).

OncologyHematology

Technology Platform

A biology-driven precision oncology platform focused on developing small-molecule inhibitors targeting key oncogenic pathways like RAS and menin-KMT2A, with an emphasis on biomarker selection and rational combination therapies to overcome treatment resistance.

Pipeline

21

21 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
Ziftomenib + Placebo + Venetoclax + Azacitidine (AZA) + Daun...	Acute Myeloid Leukemia (AML)	Phase 3
Tipifarnib	Relapsed or Refractory Peripheral T-Cell Lymphoma	Phase 2
Tipifarnib	Thyroid Cancer	Phase 2
Tipifarnib	HRAS Gene Mutation	Phase 2
Tipifarnib	Leukemia, Myelomonocytic, Chronic	Phase 2

FDA Approved Drugs

1

KOMZIFTINDANov 13, 2025

Opportunities

Kura has near-term potential to launch its first product, tipifarnib, for the underserved HRAS-mutant HNSCC population, establishing a commercial foothold.

Its deep pipeline, including ziftomenib in AML and KO-2806 as a combination backbone, provides multiple value-driving catalysts and shots on goal in large oncology markets.

Risk Factors

The company faces significant clinical trial risk, as failure of its lead programs would drastically impact valuation.

As it approaches commercialization, it also faces execution risks in launching a niche oncology product and intense competition in the menin inhibitor space for AML.

Competitive Landscape

Tipifarnib enjoys a first-mover advantage in the niche HRAS-mutant HNSCC space with limited direct competition. Ziftomenib faces strong competition from other menin inhibitors like Syndax's revumenib in AML. KO-2806's success depends on demonstrating superior combination benefit against standard-of-care therapies in competitive solid tumor markets.